SCHEMBL4022968

SCHEMBL4022968

O=C(NN1CCN(c2ccccc2)CC1)C(=O)c1cn(Cc2ccc(F)cc2)c2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.55
MAPT P10636 2/20 0.53
MAPK1 P28482 1/20 0.53
ALDH1A1 P00352 2/20 0.53
HTT P42858 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
TP53 P04637 1/20 0.52
SERPINE1 P05121 1/20 0.49
ADORA1 P30542 1/20 0.49
NPSR1 Q6W5P4 2/20 0.48
ALOX12 P18054 1/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TUBB4A P04350 1/20 0.47
TUBB P07437 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
TUBA1B P68363 1/20 0.47
TUBA4A P68366 1/20 0.47
TUBB4B P68371 1/20 0.47
TUBB3 Q13509 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086141 0.79 POLB (0.62) POLBMAPTMAPK1ALDH1A1HTT
SCHEMBL3851419 0.78 TUBB4A (0.69) POLBMAPTMAPK1ALDH1A1HTT
SCHEMBL28516015 0.77 TUBB4A (0.65) POLBMAPTMAPK1ALDH1A1HTT
SCHEMBL4022967 0.77 MAPT (0.48) POLBMAPTMAPK1ALDH1A1HTT
SCHEMBL6086686 0.76 POLB (0.74) POLBMAPTMAPK1ALDH1A1HTT
SCHEMBL30497877 0.76 POLB (0.78) POLBMAPTMAPK1ALDH1A1HTT
SCHEMBL3151543 0.73 TUBB4A (0.82) POLBMAPTMAPK1ALDH1A1HTT
SCHEMBL3844095 0.73 POLB (0.61) POLBMAPTMAPK1ALDH1A1HTT
Hydrochloric Acid SCHEMBL4920187 0.73 TUBB4A (0.81) POLBMAPTMAPK1ALDH1A1HTT
SCHEMBL27827256 0.73 L3MBTL1 (0.80) POLBMAPTMAPK1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0931063-B3 N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT ZIOPHARM ONCOLOGY INC (US) 2009-04-08 EP claimed
EP-0931063-B1 N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT BAXTER HEALTHCARE SA (CH) 2006-10-18 EP claimed
US-6919344-B2 N-substituted indole-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action ASTA MEDICA, AKTIENGESELLSCHAFT (DE) 2005-07-19 US claimed
US-20030207892-A1 N-substituted indole-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action BAXTER HEALTHCARE S.A. (CH) 2003-11-06 US claimed
US-20020161025-A1 N-substituted indole-3glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action ZIOPHARM ONCOLOGY, INC. 2002-10-31 US claimed
US-6344467-B1 ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSANT/IMMUNOMODULATING PROPERTIES ASTA MEDICA AG (DE) 2002-02-05 US claimed
EP-0931063-A1 N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT ASTA Medica Aktiengesellschaft (DE) 1999-07-28 EP claimed
WO-1998009946-A1 N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT ASTA MEDICA AKTIENGESELLSCHAFT (DE) 1998-03-12 WO claimed
EP-0931063-B3 N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT ZIOPHARM ONCOLOGY INC (US) 2009-04-08 EP disclosed
US-20080027110-A1 Indolyl-3-glyoxylic acid derivatives having antitumor action ASTA MEDICA AKTIENGESELLSCHAFT 2008-01-31 US disclosed
EP-0931063-B1 N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT BAXTER HEALTHCARE SA (CH) 2006-10-18 EP disclosed
EP-1071420-B1 INDOLYL-3-GLYOXYLIC ACID DERIVATIVES WITH ANTITUMORAL ACTIVITY BAXTER HEALTHCARE SA (CH) 2005-09-14 EP disclosed
US-6919344-B2 N-substituted indole-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action ASTA MEDICA, AKTIENGESELLSCHAFT (DE) 2005-07-19 US disclosed
US-20030023093-A1 United states patent office ASTA MEDICA AKTIENGESELLSCHAFT 2003-01-30 US disclosed
US-6232327-B1 AND PHYSIOLOGICALLY TOLERABLE ACID ADDITION SALTS, N-OXIDES ASTA MEDICA AKTIENGESELLSCHAFT (DE) 2001-05-15 US disclosed
EP-1071420-A1 INDOLYL-3-GLYOXYLIC ACID DERIVATIVES WITH ANTITUMORAL ACTIVITY ASTA Medica Aktiengesellschaft (DE) 2001-01-31 EP disclosed
US-6008231-A ANTIALLERGENS, ANTIHISTAMINES, IMMUNOSUPPRESSANTS, IMMUNOMODULATORS ASTA MEDICA AKTIENGESELLSCHGT (DE) 1999-12-28 US disclosed
WO-1999051224-A1 INDOLYL-3-GLYOXYLIC ACID DERIVATIVES WITH ANTITUMORAL ACTIVITY ASTA MEDICA AKTIENGESELLSCHAFT (DE) 1999-10-14 WO disclosed
EP-0931063-A1 N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT ASTA Medica Aktiengesellschaft (DE) 1999-07-28 EP disclosed
WO-1998009946-A1 N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT ASTA MEDICA AKTIENGESELLSCHAFT (DE) 1998-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030023093-A1 United states patent office IDO1, IDO2, TDO2 POLB 3037/4885MAPT 3529/4885MAPK1 3834/4885
US-20030207892-A1 N-substituted indole-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action IDO1, IDO2, INMT POLB 4834/4885MAPT 3185/4885MAPK1 4718/4885
US-20080027110-A1 Indolyl-3-glyoxylic acid derivatives having antitumor action IDO1, IDO2, TDO2 POLB 2556/4885MAPT 3557/4885MAPK1 4016/4885
US-20020161025-A1 N-substituted indole-3glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action IDO1, IDO2, INMT POLB 4855/4885MAPT 3626/4885MAPK1 4741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.